FDA.reportPublic FDA data

Impavido Pill

RxCUI
1495069
RxNorm name
Impavido Pill
Term type
SBDG
Status
Active
Updated
2026-10-04 02:02:41

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
052014
Active start
052014
Multiple ingredient
NO
Branded
YES

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
miltefosine1494066

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRImpavido Pill1NAMES
RxNorm NameImpavido Pill1NAMES
TTYSBDG1ATTRIBUTES
RxCUI14950691CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 0 matching rows.

No records found.

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCP01CXOther agents against leishmaniasis and trypanosomiasisATC1-4miltefosine
FDASPLN0000190851AntileishmanialEPChas_epcmiltefosine
MEDRTD010767PhosphorylcholineCHEMhas_ingredientmiltefosine
MEDRTD004342Drug HypersensitivityDISEASEci_withmiltefosine
MEDRTD016773Leishmaniasis, CutaneousDISEASEmay_treatmiltefosine
MEDRTD007898Leishmaniasis, VisceralDISEASEmay_treatmiltefosine
MEDRTD011247PregnancyDISEASEci_withmiltefosine
MEDRTD016111Sjogren-Larsson SyndromeDISEASEci_withmiltefosine
MEDRTN0000181812Lysophospholipid Receptor InteractionsMOAhas_moamiltefosine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH50 MG
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESRXNAV_HUMAN_DRUGUS